By safeguarding the BBB, SGLT-2 inhibitors may prevent the influx of harmful substances into the brain, thus reducing the risk of neurodegeneration and cognitive decline in patients with diabetes. The gene discussed is SLC5A2; the disease is diabetes mellitus.